Tolremo doses first patient in phase 1 trial for drug to combat transcriptional cancer drug resistance
Betsy Goodfellow | November 29, 2023 | News story | Research and Development | Oncology, Tolremo, clinical trial, drug resistance, solid tumours
Tolremo Therapeutics has announced that it has dosed the first patient in its first-in-human clinical trial to assess the safety, efficacy, pharmacokinetics and pharmacodymanics of TT125-802 in patients with a range of solid tumours.
TT125-802 is an orally available small molecule CBP/p300 bromodomain inhibitor intended to prevent non-genetic cancer drug resistance, as well as improve response rates and durability of targeted cancer treatments.
It appears from preclinical testing, that the drug is able to block critical transcriptional resistance pathways that are responsible for cancer’s ‘escape mechanisms’ to targeted therapies.
The phase 1 study is expected to enroll patients with a range of solid tumours, primarily in order to assess the safety of the compound, with secondary objectives including the analysis of its biological activity, pharmacokinetics, pharmacodynamics and target engagement, along with identifying recommended doses and potential biomarkers.
Stefanie Flückiger-Mangual PhD, co-founder and chief executive officer of Tolremo, commented: “Initiating our phase 1 clinical trial is an important corporate milestone for Tolremo. With TT125-802, we are leveraging our scientific insights to develop an effective CBP/p300 inhibitor with the potential to prevent resistance mechanisms across a broad spectrum of current and future targeted cancer treatments. We are deeply committed to overcoming transcriptionally mediated cancer drug resistance for patient benefit, and this trial marks the start of an exciting new phase for the company.”
Betsy Goodfellow
Related Content
SMC accepts atogepant for acute migraine treatment in Scotland
The Scottish Medicines Consortium (SMC) has accepted AbbVie’s Aquipta (atogepant) as an option for the …
Amphista doses first patient in AML trial of protein degrader
Amphista Therapeutics has dosed the first patient in a phase 1 trial of AMX-883, an …
Tridem begins phase Ib trial of Parkinson’s disease vaccine
Tridem Bioscience has enrolled the first patients in a phase Ib clinical trial of TRB-001, …
